ningaloo biosystems GmbH

Many newly developed drugs for cancer and autoimmune diseases are extremely expensive to produce. This is mainly due to the fact that the processes—especially in the bioreactors where these active ingredients are manufactured—are still highly inefficient. The biotech startup ningaloo biosystems is developing products that enable biopharmaceutical manufacturers to produce more efficiently and in a more standardized way, and to reduce their currently largely prohibitive costs through higher yields. ningaloo biosystems’ platform technology for “opto-bioproduction” is based on insights from optogenetics and, for the first time, makes it possible to control processes in the bioreactor in real time using light. This helps conserve resources and ultimately makes novel biopharmaceuticals affordable for millions of patients.